Exhibit 99.1

 

GRAPHIC

 

 

 

Contact:

Monique Greer

720-540-5268

mgreer@allos.com

 

Allos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results

 

- Conference Call Scheduled for Today at 4:30 p.m. ET -

 

WESTMINSTER, Colo., March 3, 2011

— Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported financial results for the fourth quarter and full year ended December 31, 2010.

 

Financial Highlights:

 

·                  In January 2010, the Company commenced the commercial launch of FOLOTYN® (pralatrexate injection) — the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

 

·                  $11.8 million in gross product sales to health care providers for the fourth quarter 2010, a 27 percent sequential increase over third quarter 2010.

 

·                  $11.7 million and $35.2 million in net product sales for the fourth quarter and full year 2010, respectively.

 

·                  $98.6 million in total cash and investments and no debt as of December 31, 2010.

 

“We made important progress during 2010, including the launch of FOLOTYN in the United States and the build-out of our commercial infrastructure,” said Paul L. Berns, president and chief executive officer of Allos Therapeutics.  “We are encouraged by the initial trial, use and adoption of FOLOTYN in the first full year of commercialization.  We believe the market opportunity for relapsed or refractory PTCL is substantial, and our goal is to establish FOLOTYN as the standard of care for this patient population.  Our key objectives in 2011 include driving U.S. sales of FOLOTYN for relapsed or refractory PTCL, advancing studies of FOLOTYN in other hematologic malignancies and expanding the commercial potential of FOLOTYN outside the U.S. through a potential strategic partnership and pursuing regulatory approval in the EU.”

 

Allos sells FOLOTYN to pharmaceutical wholesale distributors who then resell FOLOTYN to patients’ health care providers.  As previously reported, the Company’s fourth quarter 2010 sales, including a comparison to the third quarter 2010, are summarized as follows:

 

1


The following information was filed by Allos Therapeutics Inc (ALTH) on Thursday, March 3, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Allos Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allos Therapeutics Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account